Ceraxon ® 10 g/100 ml vial. 30 ml
Ceraxon ® 30 ml of p-d / peroral. ca. Valium.
Structure and Composition:
Tsitikolin 10 g/100 ml
Other ingredients: sorbitol, glycerol, Nipagin, nipazol, glitserinformal, sodium citrate (dihydrate), sodium saharinat, dye ponceau 4R, strawberry essence, potassium sorbate, citric acid, purified water.
tsitikolin stimulates the biosynthesis of structural membrane phospholipids of neurons, which improves the function of membranes, including the operation of ion exchange pumps and neuroreceptors. Thanks to the stabilizing effect on the membrane tsitikolin has anti-edematous properties and reduces the swelling of the brain. Tsitikolin reduces symptoms of cerebral dysfunction after such pathological processes, such as traumatic brain injury or acute disorders of cerebral circulation. Tsitikolin reduces the level of amnesia, improves with cognitive, sensitive and motor disorders, also reduces the severity of symptoms that occur during hypoxia and ischemia of the brain, including memory impairment, emotional lability, impaired ability to perform normal activities of self-care.
Tsitikolin is a natural compound contained in the human body, so the classical pharmacokinetic studies may not be possible given the complexity of the quantitative determination of exogenous and endogenous tsitikolina. In the pharmacokinetic study determined the almost complete its absorption in the gastrointestinal tract - less than 1% of the dose was found in the feces within 5 days after ingestion. It was also noted two peaks of radioactivity in blood plasma by metabolism in the liver and gut: the first - after 1 h, the second - after 24 hours
Bioavailability after oral and parenteral routes of administration are virtually identical. Excretion - very slow, mainly through the respiratory organs and excretion. After 5 days of reception was revealed about 16% of the dose, indicating that the inclusion of the rest of the dose to metabolic processes.
acute phase of stroke;
treatment of complications and sequelae of cerebrovascular;
traumatic brain injury and its consequences;
cognitive, sensitive, motor and neurological disorders caused by cerebral pathology is degenerative and vascular origin.
rr for oral use an adult appointed interior, 200 mg (2 ml) 3 times a day. Children drug can be given by mouth from birth - 100 mg (1 ml) 2-3 times per day.
Duration of treatment depends on the severity of brain damage. Minimum recommended period - 45 days.
Dose and duration of treatment may be changed by your doctor.
The drug, previously mixed with a small amount of water taken using the dosing syringe. Should be cleaned with the dosing syringe with water after each use.
should not be administered to patients with a high tone of the parasympathetic nervous system.
in rare cases Tserakson can stimulate the parasympathetic nervous system, as well as provide short-term hypotensive effect.
Prolonged use tsitikolina not accompanied by toxic effects, regardless of the method of administration.
age limits for oral administration of the drug there.
During pregnancy and lactation. Although the evidence of risk to the fetus in the application of the drug has not been received, during pregnancy medication used only if the expected benefit outweighs the potential risk. Data on the flow tsitikolina into breast milk and no effects on the fetus are not known.
Effects on ability to drive a motor vehicle and work with complex arrangements. Tsitikolin not affect the ability to drive a motor vehicle and work with complex arrangements.
tsitikolin enhances the effect of levodopa. The drug should not be given concurrently with medicinal products containing meklofenoksat.
cases were not described, given the low toxicity, even in excess of therapeutic doses.
at a temperature above 30 ° C, shelf life - 3 years.
Ceraxon ® 10 g/100 ml vial. 30 ml
- Product Code: 45
- Availability: In Stock
- Ex Tax: $98.00